Active Clinical Trials and Research Studies
This is a Phase 3, safety and efficacy study of Dimebon for the treatment of Alzheimer's disease. Study participants are asked to come for study-related visits 10 times during a 1-year period, take study medications as directed by study personnel, and complete all study-related procedures.
ELIGIBILITY CRITERIA
Inclusion criteria:
1. Have mild to moderate Alzheimer's disease.
2. Be 50 years of age or older.
3. Have been taking Aricept (Donepezil) for at least 6 months.
We are now enrolling men and women, ages 45 to 90, with memory loss or mild cognitive impairment (MCI) to participate in this study. A study partner will also be needed to participate in this study. Volunteers may receive investigational medication, study-related medical care, laboratory testing and cognitive testing.
We are seeking Alzheimer's disease patients to evaluate the safety of a new investigational drug called ACC-001 that may be a possible treatment for Alzheimer's disease. ACC-001 is an investigational drug not currently-approved by the US Food and Drug Administration (FDA).
We are seeking patients with mild to moderate Alzheimer's disease to evaluate the tolerability, safety and effectiveness of a new investigational drug that may be a possible treatment for Alzheimer's disease. Bapinuzemab is an investional drug not currently-approved by the US Food and Drug Administration (FDA).
We are seeking healthy adults, 55 to 90 years of age to participate in a research study. The goal of the study is to determine whether imaging of the brain (through MRI, PET and amyloid imaging scans) can help predict and monitor the onset and progression of Alzheimer's disease.
In addition to neuroimaging, the study will collect and test blood and cerebral spinal fluid to determine if biomarkers can predict and monitor the disease. Testing cerebral spinal fluid is the only way to obtain important brain information.
The purpose of the study is to develop ways for understanding memory changes that occur with age. Participants will be asked questions about their memory and must have a friend or relative who can answer ten minutes of questions over the telephone about day-to-day activities.
If you qualify, you will be asked to have three brain scans and follow-up memory testing at 12 & 24 months after the initial visit. All evaluations will be free of cost and reimbursement for time and transportation is provided. All information is kept completely confidential..
We are seeking adults, sixty-five years of age or order, with at least four years of education, from a variety of ethnic backgrounds to participate in a research study. The purpose of the study is to develop simple methods for understanding memory changes with age.
DIAN stands for the Dominantly Inherited Alzheimer’s Network. This international network has been established by the National Institute on Aging of the National Institutes of Health (US) to bring together researchers who study genetic forms of Alzheimer’s disease (AD).
We are seeking healthy volunteers and individuals with Mild Cognitive Impairment (MCI) or Mild Alzheimer's Disease (AD) who are interested in taking part in a clinical research study to find out if functional MRI images of the brain can be used to diagnose and monitor the course and treatment of MCI and AD. Subjects must have a study partner and be willing to come to six to eight clinic visits over the course of two to three years.
We are seeking healthy adults to participate in a research study. The purpose of the study is to develop ways for understanding memory changes that occur with age. Participants will be asked questions about their memory and must have a friend or relative who can answer ten minutes of questions over the telephone about day-to-day activities.
